In this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer’s disease research in a laboratory at the drugmaker’s headquarters in Cambridge, Mass. On Friday, Nov. 6, 2020, a panel of outside experts will meet to advise the Food and Drug Administration on the drug, called aducanumab from Biogen Inc. and Japan’s Eisai Co. The drug does not cure or reverse Alzheimer’s; the claim is that it modestly slows the rate of decline. (David A. White/Biogen via AP)
One of the biggest drug decisions in decades is looming as U.S. regulators consider whether to approve the first medicine that’s claimed to slow mental decline from Alzheimer’s disease, the most common form of dementia.
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...
